Category: Trikafta

A recent study from the UK has predicted that Trikafta may increase the life expectancy of those aged 12+ with two F508del to a median age of 71.6!! This is +33 years compared to best supportive care and +23 years compared to Symdeko! These findings are based on a microsimulation prediction involving the phase 3…

Disappointingly Trikafta for 6-11s is going back to the PBAC as an agreement has not been reached. It will be discussed this week with the outcome released on April 21. This is not good enough Mark Butler MPVertex Pharmaceuticals. Heading back to the standard PBAC process leads to further uncertainty with the approval and timeframe,…

The medicine status website was updated this week and shows that step 5 of 8 is underway. Whilst there are multiple parts within each step, the progress is underwhelming for those who are seriously unwell now. Some of these children are in hospital right now and urgently need access to Trikafta. Every day matters for…

When you have a life shortening illness, it’s all about the important moments with your family and friends. These children had to spend time in hospital over the festive season and missed those special moments. Trikafta is a life-saving medication that can change all this, giving these kids the chance to live a longer, healthier…

Have a read below about what happens after a PBAC meeting & what we can do to help fast track the listing! What happens after a PBAC meeting? After a positive recommendation, there are several steps before a medication can be listed on the PBS. Amongst these steps are the negotiations between the Department of…

Great news it’s a yes! Trikafta for children aged 6-11 has received a positive recommendation, moving much closer toward access However this recommendation has not been given a priority pathway for listing (which Trikafta for 12+ had), so we need to make sure the next step, involving further negotiations, happens as quickly as possible! The…

This is great news for the approx. 500 children waiting for Trikafta around Australia. Our children with Cystic Fibrosis might look healthy now but inside they are already fighting an immense battle. Together we can let the PBAC know just how important it is that these children and families hear good news in 2022! You…

~ Trikafta is on the PBS as of today!! ~ This wouldn’t have happened without the amazing scientists at Vertex. Funding from the Cystic Fibrosis Foundation helped Vertex Pharmaceuticals to develop the first CFTR modulator, Kalydeco, by testing 228,000 compounds! Since then Orkambi, Symdeko and Trikafta have been developed, meaning there is a highly effective…